In patients with high risk, locally advanced cervical cancer, previously reported data demonstrated an advantage for the immune checkpoint inhibitor pembrolizumab (Keytruda, Merck) over concurrent chemoradiotherapy (CCRT) alone for progression-free survival (PFS), but mature data now show the efficacy advantage extends to overall survival (OS). The OS data (abstract 7090) were presented at the 2024 European Society for Medical Oncology Congress, in Barcelona.
Even though pembrolizumab already